$CORT

Lyon Joseph Douglas sold $325K of CORT

Lyon Joseph Douglas (See Remarks) sold 5,000 shares of CORCEPT THERAPEUTICS INC (CORT) at $65.00 ($0.32M total) on 2026-05-27.

Original reporting
SEC EDGAR · Lyon Joseph Douglas
Published May 29, 2026, 10:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 10:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or correlate with broader tape/valuation moves, but the filing alone does not change fundamentals.

02

Market read

Provides a discrete insider selling datapoint that can slightly influence sentiment, with limited direct trading edge absent additional fundamental catalysts.

03

What to watch

The transaction is explicitly noted as not under a pre-arranged 10b5-1 plan, which can increase perceived signal—but the article lacks context on prior holdings, sale frequency, or tax/portfolio constraints.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed May 29 (covering sale on May 27)

Background

The article is an SEC insider transaction disclosure (Form 4) for Corcept Therapeutics, reporting an officer’s open-market sale.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics officer Lyon Joseph Douglas sold 5,000 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Low, likely limited to short-term sentiment/flow effects rather than a sustained repricing.

Evidence & confidence

The filing provides a single insider sale datapoint (value ~$325k) without any accompanying operational or guidance change; impact is typically modest unless part of a broader pattern.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide signal.

None indicated.

None indicated.

Counterpoint

A one-off insider sale may reflect diversification or liquidity needs and may not signal reduced confidence, especially without a larger sequence of sales.

Key entities

  • Corcept Therapeutics Inc

    Subject of the SEC Form 4 insider sale disclosure.

  • Lyon Joseph Douglas

    Officer who sold 5,000 shares of CORT on May 27, filed May 29.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

$CORTHighAI 8/10

CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally

Corcept Therapeutics (CORT) shares rose 7% to their highest 2026 levels after announcing plans to resubmit its NDA for Relacorilant, a Cushing’s syndrome treatment, following positive FDA discussions. The FDA rejected the initial filing in December, citing insufficient effectiveness data. The company expects a PDUFA date six months post-submission. CORT shares are down 27% year-to-date, with retail sentiment remaining bearish.

$CORTHighAI 9/10

Corcept Therapeutics Incorporated: Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli (Relacorilant)

Corcept Therapeutics (CORT) announced the European Medicines Agency's CHMP recommended EU approval for relacorilant, combined with nab-paclitaxel, to treat platinum-resistant ovarian cancer. The recommendation follows positive Phase 2 and Phase 3 trial results showing improved survival rates. The EC will decide by Q4 2026. Relacorilant is already FDA-approved in the U.S. for the same indication.

$CORTHighAI 9/10

Raised Guidance Lifts Corcept to 52-Week High

Corcept Therapeutics (CORT) reported fiscal 2026 Q2 results with record revenue of $256.1 million, up 32% year over year, and net income of $43 million, up 22.9%. The company had $545 million in cash and investments and raised 2026 revenue guidance to as much as $1.2 billion, sending shares to a 52-week high.

$MSFTHighAI 8/10

Stocks Rally on Stellar Microsoft Earnings and Chip Stock Strength

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.